(0.35%) 5 117.73 points
(0.34%) 38 368 points
(0.40%) 15 992 points
(-0.98%) $83.03
(5.51%) $2.03
(0.33%) $2 354.90
(0.46%) $27.66
(4.08%) $959.70
(-0.26%) $0.932
(-0.42%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
@ $8.91
発行日: 15 2月 2024 @ 04:26
リターン: -19.75%
前回のシグナル: 2月 14 - 05:22
前回のシグナル:
リターン: -1.22 %
Live Chart Being Loaded With Signals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States...
Stats | |
---|---|
本日の出来高 | 64 460.00 |
平均出来高 | 638 458 |
時価総額 | 442.84M |
EPS | $0 ( 2024-02-27 ) |
次の収益日 | ( $-0.440 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.50 |
ATR14 | $0.0110 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Horn Patrick Taylor | Buy | 400 000 | Stock Option (right to buy) |
2024-03-18 | Horn Patrick Taylor | Sell | 0 | No securities are beneficially owned |
2024-03-08 | Tourangeau Greg | Sell | 4 884 | Common Stock |
2024-03-04 | Sapir Alex | Buy | 43 360 | Common Stock |
2024-01-26 | Tourangeau Greg | Buy | 83 820 | Stock Option (right to buy) |
INSIDER POWER |
---|
20.76 |
Last 98 transactions |
Buy: 8 691 029 | Sell: 9 119 346 |
ボリューム 相関
Fulcrum Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
RDUS | -0.927 |
XOG | -0.9 |
TYHT | -0.895 |
EPZM | -0.881 |
OPCH | -0.871 |
SYKE | -0.868 |
HSTM | -0.864 |
CNCE | -0.856 |
CRWD | -0.848 |
ICON | -0.846 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Fulcrum Therapeutics Inc 相関 - 通貨/商品
Fulcrum Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $2.81M |
総利益: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2023 |
収益: | $2.81M |
総利益: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2022 |
収益: | $6.34M |
総利益: | $3.93M (61.94 %) |
EPS: | $-2.35 |
FY | 2021 |
収益: | $19.16M |
総利益: | $19.16M (100.00 %) |
EPS: | $-2.29 |
Financial Reports:
No articles found.
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。